Results 161 to 170 of about 7,154 (184)

Nirmatrelvir–ritonavir compared with other antiviral drugs for the treatment of COVID‐19 patients: A systematic review and meta‐analysis

Journal of Medical Virology, 2023
Fangyuan Tian, Zhaoyan Chen
exaly  

Carfilzomib/nirmatrelvir+ritonavir

Reactions Weekly, 2023
openaire   +1 more source

Nirmatrelvir Use during the Omicron Surge

New England Journal of Medicine, 2022
Maaike C, Swets, Mark G J, de Boer, Geert H, Groeneveld   +2 more
openaire   +4 more sources

Adverse Events Associated with Nirmatrelvir/Ritonavir: A Pharmacovigilance Analysis Based on FAERS

Pharmaceuticals, 2022

exaly  

Molnupiravir compared to nirmatrelvir/ritonavir for COVID-19 in high-risk patients with haematological malignancy in Europe. A matched-paired analysis from the EPICOVIDEHA registry

International Journal of Antimicrobial Agents, 2023
Jon Salmanton-Garcia, Francesco Marchesi, Iker Falces-Romero   +2 more
exaly  

Nirmatrelvir+ritonavir/tozinameran

Reactions Weekly, 2023
openaire   +1 more source

Nirmatrelvir for Nonhospitalized Adults with Covid-19

New England Journal of Medicine, 2022
Brian S, Chen, Cheng-Hsien, Hung, James C-C, Wei   +2 more
openaire   +3 more sources

Prevalence of Medical Contraindications to Nirmatrelvir/Ritonavir in a Cohort of Hospitalized and Nonhospitalized Patients With COVID-19

Open Forum Infectious Diseases, 2022
Sarah Lim, Christopher J Tignanelli, Nicolas Hoertel   +2 more
exaly  

Use of Ritonavir-Boosted Nirmatrelvir in Pregnancy

Clinical Infectious Diseases, 2022
George K, Siberry, Lynne M, Mofenson, Alexandra, Calmy, Uma M, Reddy, Elaine J, Abrams   +4 more
openaire   +2 more sources

Nirmatrelvir and ritonavir

Clinical Therapeutics
openaire   +2 more sources